Hip Fracture Risk in Patients With a Diagnosis of Pernicious Anemia

 Conflicts of interest The authors disclose the following: Dr Metz reports serving as a consultant and receiving honoraria and/or grant support from AstraZeneca, TAP Pharmaceutical Products, Altana, Wyeth-Ayerst Laboratories, Santarus, and Eisai. Dr Yang reports having served as a consultant for AstraZeneca and received grant support from AstraZeneca and GlaxoSmithKline. The remaining auhors disclose no conflicts.

 Funding Dr Merriman was supported by a National Institutes of Health educational training grant during his gastroenterology and epidemiologic training at the University of Pennsylvania. Dr Yang was supported by a National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases Mentored Career Development Award (K08 DK062978), which also funded the access to the data in the General Practice Research Database. This study was supported by an academic development fund from the University of Pennsylvania to Dr Yang. The funding sponsors played no role in the study design in the collection, analysis, and interpretation of data.

PII: S0016-5085(09)02145-3

doi: 10.1053/j.gastro.2009.12.007

© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.